All In Biotech

Drug Trial Radar · NCT05507515

A Phase 1 Study of ONO-2020 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Five-part Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2020 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

132

Actual

Start

Jul 29, 2022

Primary completion

Dec 24, 2023

Study completion Dec 24, 2023

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.

Conditions

  • Healthy Volunteers

Interventions

  • ONO-2020Drug

    ONO-2020 tablets

  • PlaceboDrug

    Placebo tablets matching ONO-2020 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and type of treatment emergent adverse events (TEAEs)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  2. Vital signs (blood pressure)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  3. Vital signs (pulse rate)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  4. Vital signs (body temperature)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  5. Vital signs (respiratory rate)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  6. 12-lead electrocardiograms (ECGs) parameters, such as but not limited to heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  7. Clinically significant abnormal telemetry electrocardiograms (ECGs)Time frame: Part A and D: Day 1
  8. Clinically significant abnormal physical examination findingsTime frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  9. Clinical laboratory abnormalities (hematology, clinical chemistry, coagulation, and urinalysis)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  10. Ophthalmologic examination findings (pupil size and pupillary light reflex)Time frame: Part A, C and D: From Day 1 up to Day 7, Part B and E: From Day 1 up to Day 21
  11. Clinically abnormal findings in Mini-International Neuropsychiatric Interview Screen (M.I.N.I.-Screen)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
  12. Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.